VectorY

Welcome to Adam Rosenberg as the new Chair of VectorY! Boston-based Mr Rosenberg brings over 20 years of experience in building and leading life sciences companies, primarily in the neuroscience space. He is taking over from Dr Carlo Incerti who we thank for his leadership, guidance and dedication since VectorY’s founding. The appointment comes at a pivotal time for VectorY as the company advances towards clinical development with a pipeline of strongly differentiated vectorized antibody treatments for neurodegenerative disorders. For a full version of the release, please visit the website at https://lnkd.in/e34UaG2W

VectorY Therapeutics is hiring! Are you an enthusiastic and experienced scientist interested in joining our vector development team? Check out the link for more details. #VectorY #ALS #neurogenerativediseases #biotech #genetherapy #Amsterdam #scientist #vectordevelopment #PhD #Sciencepark #vacancy #careeropportunity #hiring

Our CCO, Elena Ritsou, will attend the J.P. Morgan European Healthcare Symposium in London on June 20. The symposium brings together industry leaders, investors, and innovative healthcare companies to discuss advancements in life sciences. #VectorY #GeneTherapy #neurodegeneration #biotechnology #biotech

We’re excited to be collaborating on a new study with UMC Utrecht to identify #biomarkers of #AmyotrophicLateralSclerosis (#ALS). The observational investigator-initiated study, which has already enrolled its first patient, is led by Professor Dr. Leonard van den Berg, Professor of #Neurology at UMC Utrecht.   Our CEO, Sander van Deventer, commented: "In recent years, key hallmarks of ALS pathogenesis have been elucidated, enabling the development of novel, potentially disease-modifying therapies. However, clinical development of these therapies is critically dependent on the availability of easily-measurable biomarkers that reflect the underlying pathogenesis.”   Professor van den Berg added: “When more objective biomarkers are available it will be easier to identify effective treatment options. That is always the main goal: to find an effective treatment for everyone living with ALS as quickly as possible.” Read the full news update: https://lnkd.in/eKH2x5eF #VectorY #GeneTherapy #neurodegeneration #biotechnology #biotech

Our CEO, Sander van Deventer, will attend the European Network to Cure ALS (ENCALS) 2024 Annual Meeting on June 17-19 at the Karolinska Institute in Stockholm, Sweden. ENCALS connects researchers and advocates from Europe and beyond to share the latest research and advancements aimed at supporting individuals living with ALS. Read the full news update: https://lnkd.in/e6iguzkC #VectorY #GeneTherapy #neurodegeneration #biotechnology #biotech

Many congratulations to Giulia De Sabbata on her promotion to Head of Discovery at VectorY Therapeutics! #VectorY #genetherapy #biotech #promotion #research #discovery #career #sciencepark #Amsterdam #ALS

We are very happy to welcome Mahtab Foroughi and Laurens Schuurmans to our team at VectorY. Mahtab will be joining us as an intern at our Translational Biomarker Group with Rob Haselberg as internship host. Laurens will join our Discovery group with Svetlana Pasteuning-Vuhman 🇺🇦 as internshiphost. All VectorYans wish you a great time at VectorY Therapeutics. #VectorY #internship #genetherapy #biotechnology #ALS

VectorY Therapeutics is hiring! Are you an enthusiastic and experienced scientist interested in joining our assay development team? Check out the link for more details: https://lnkd.in/e8mCNfjR #vectory #assaydevelopment #hiring #ALS #vacancy #scientist #PhD #neurogenerativediseases #career #opportunity #sciencepark #Amsterdam

We are very happy to welcome Joshua Kanters to our team at VectorY. Joshua will be joining us as an intern at our PD department for the next 6 months. We wish him the best of luck in his new role! #VectorY #internship #PDdepartment #genetherapy #biotechnology #ALS

We are excited to share that Desiree Lathouwers has joined our team at VectorY as the new Head of QA. Welcome aboard Desiree!